Chrome Extension
WeChat Mini Program
Use on ChatGLM

Position paper of the working group Chronic Inflammatory Bowel Diseases of the oGGH on the use of vedolizumab subcutaneously

ZEITSCHRIFT FUR GASTROENTEROLOGIE(2023)

Cited 0|Views9
No score
Abstract
The humanized monoclonal anti-alpha 4 beta 7-integrin-antibody vedolizumab is one of several biologic therapeutic options in moderate-to-severe ulcerative colitis and Crohn's disease. Within the VISIBLE trial program, a novel subcutaneous application route was evaluated in addition to the already established intravenous form. In this position statement, the working group "Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology (OEGGH) summarizes the evidence regarding the subcutaneous application of vedolizumab. This work supplements a position paper on the value of vedolizumab as a first-line biologic that has already been published and offers useful recommendations for clinical practice.
More
Translated text
Key words
Inflammatory Bowel Disease,Ulcerative Colitis,Crohn's Disease
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined